17 completed, 13 terminated, 2 active not recruiting, 2 recruiting. 23 Phase 2, 16 Phase 1, 2 Phase 3.
Follow INC280: new trials by email Literature Review of INC280 trials Research Report on INC280
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) Biospecimen Collection, Capmatinib, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 66 | 2023-05-05 | 2026-06-03 |
| Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Capmatinib, Trametinib - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer | Phase 1 | Terminated | Collin Blakely | 3 | 2022-08-10 | 2024-06-11 |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC capmatinib - Non-small Cell Lung Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 4 | 2022-08-10 | 2025-10-16 |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma Capmatinib, Spartalizumab - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 90 | 2022-03-22 | 2023-02-03 |
| Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy Capmatinib, Osimertinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Novartis Pharmaceuticals | 6 | 2021-09-22 | 2024-03-05 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2021-05-17 | 2026-03-31 |
| Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Novartis Pharmaceuticals | 22 | 2020-09-25 | 2025-05-16 |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations Spartalizumab, Capmatinib, spartalizumab placebo - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Novartis Pharmaceuticals | 31 | 2020-08-19 | 2024-10-09 |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% Capmatinib, Pembrolizumab - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Novartis Pharmaceuticals | 76 | 2020-01-22 | 2024-10-09 |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). spartalizumab, LAG525, NIR178 - Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Novartis Pharmaceuticals | 64 | 2019-01-31 | 2025-05-18 |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Capmatinib, Spartalizumab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Novartis Pharmaceuticals | 18 | 2018-12-26 | 2022-01-24 |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma PDR001, LAG525, INC280 - Melanoma | Phase 2 | Completed | Novartis Pharmaceuticals | 196 | 2018-09-10 | 2024-06-18 |
| Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) INC280 - Carcinoma, Non-Small-Cell Lung Cancer | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-07-31 | 2018-07-26 | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC EGF816, trametinib, ribociclib - EGFR-mutant Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 105 | 2018-01-29 | 2026-11-05 |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone Capmatinib, Nazartinib, Gefitinib - Advanced Solid Tumors Which Are cMET-dependent | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 29 | 2017-07-04 | 2026-09-09 |
| A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. INC280 - cMET Dysegulation Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 36 | 2016-12-14 | 2020-12-19 |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma INC280, Placebo - Advanced Hepatocellular Carcinoma | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-12-01 | 2016-09-01 | |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Spartalizumab, Capmatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 89 | 2016-06-15 | 2023-07-03 |
| A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors INC280, Midazolam, Caffeine - cMET-dysregulated Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 37 | 2015-12-10 | 2020-12-10 |
Showing 20 of 38. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (18) · Lung Neoplasms (6) · Adenocarcinoma of Lung (5) · Glioblastoma (3) · Melanoma (3) · Neoplasm Metastasis (3) · Carcinoma (2) · Colorectal Neoplasms (2) · Gliosarcoma (2) · Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Brain Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Kidney Neoplasms (1)
Novartis Pharmaceuticals (29) · Assistance Publique - Hôpitaux de Paris (1) · Collin Blakely (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · SCRI Development Innovations, LLC (1) · SWOG Cancer Research Network (1) · University of California, Davis (1) · University of California, San Francisco (1)
United States (24) · Spain (20) · Germany (18) · Italy (18) · France (17) · Netherlands (11) · Canada (10) · Singapore (10) · Australia (9) · Belgium (9) · South Korea (9) · Hong Kong (7) · Japan (7) · Taiwan (7) · United Kingdom (7)
Adil Daud (1) · Birgit Geoerger, MD (1) · Collin M Blakely, MD, PhD (1) · Karen Kelly (1) · Kent C. Shih, M.D. (1) · Ramaprasad Srinivasan, M.D. (1) · Sarah B Goldberg (1)
PMID 26825170, PMID 30156984, PMID 31538815, PMID 31776899, PMID 31778267, PMID 31853265, PMID 32240796, PMID 32410080, PMID 32877583, PMID 33892407, PMID 34046915, PMID 34053700, PMID 34347542, PMID 34376578, PMID 34543871, PMID 35292802, PMID 36822130, PMID 38617599, PMID 38763104, PMID 38986421, PMID 39362249, PMID 41838385, PMID 41914670, PMID 42686334
2014 (4), 2018 (3), 2016 (2), 2019 (2), 2015 (1), P30CA093373 (1), U10CA180888 (1)